Intermittent hypoxia selects for genotypes and phenotypes that increase survival, invasion, and therapy resistance

PLoS ONE

Volumn 10, Issue 3, 2015, Pages

  Verduzco, Daniel ^a   Lloyd, Mark ^a   Xu, Liping ^a   Ibrahim Hashim, Arig ^a   Balagurunathan, Yoganand ^a   Gatenby, Robert A ^a   Gillies, Robert J ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBONATE DEHYDRATASE IX; DOCETAXEL; ETOPOSIDE; GLUCOSE TRANSPORTER 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; METHOTREXATE; PROTEIN P53; REACTIVE OXYGEN METABOLITE; UVOMORULIN; BIOLOGICAL MARKER; CADHERIN;

ADAPTATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER GROWTH; CELL HYPOXIA; CELL INVASION; CELL PROLIFERATION; CELL SURVIVAL; CHROMOSOME LOSS; CONTROLLED STUDY; ENVIRONMENTAL STRESS; EPITHELIAL MESENCHYMAL TRANSITION; EPITHELIUM CELL; FEMALE; GENE AMPLIFICATION; GENE MUTATION; GENOTYPE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; INTRADUCTAL CARCINOMA; MOUSE; NONHUMAN; PHENOTYPE; PROTEIN EXPRESSION; THERAPY RESISTANCE; TUMOR GENE; TUMOR INVASION; UPREGULATION; ANIMAL; DISEASE MODEL; DRUG RESISTANCE; GENETIC ASSOCIATION STUDY; GENETICS; HYPOXIA; METABOLISM; MORTALITY; NEOPLASM; PATHOLOGY; TUMOR CELL LINE; TUMOR STEM CELL ASSAY;

ANIMALS; BIOMARKERS; CADHERINS; CELL HYPOXIA; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, NEOPLASM; GENETIC ASSOCIATION STUDIES; GENOTYPE; GLUCOSE TRANSPORTER TYPE 1; HUMANS; HYPOXIA; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MICE; NEOPLASM INVASIVENESS; NEOPLASMS; PHENOTYPE; TUMOR STEM CELL ASSAY; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84926328623     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0120958     Document Type: Article

References (59)

1. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-674. doi: 10.1016/j.cell.2011.02.013 PMID: 21376230
2. Gatenby RA, Gillies RJ. A microenvironmental model of carcinogenesis. Nature reviews. 2008; 8 (1):56-61. PMID: 18059462
3. Fletcher GH. Radiation and drug resistance of breast cancer. Am J Clin Oncol. 1984; 7(6):617-624. PMID: 6528860
4. Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN. Overview of resistance to systemic therapy in patients with breast cancer. Adv Exp Med Biol. 2007; 608:1-22. PMID: 17993229
5. Zhou J, Schmid T, Schnitzer S, Brune B. Tumor hypoxia and cancer progression. Cancer Lett. 2006; 237(1):10-21. PMID: 16002209
6. Hockel M, Vaupel P. Biological consequences of tumor hypoxia. Semin Oncol. 2001;28(2 Suppl 8:):36-41. PMID: 11395851
7. Aktipis CA, Kwan VS, Johnson KA, Neuberg SL, Maley CC. Overlooking evolution: a systematic analysis of cancer relapse and therapeutic resistance research. PLOS One. 2011; 6(11):e26100. doi: 10.1371/journal.pone.0026100 PMID: 22125594
8. Wojtkowiak JW, Verduzco D, Schramm KJ, Gillies RJ. Drug resistance and cellular adaptation to tumor acidic pH microenvironment. Mol Pharm. 2011; 8(6):2032-2038. doi: 10.1021/mp200292c PMID: 21981633
9. Cardaci S, Ciriolo MR. TCA Cycle Defects and Cancer: When Metabolism Tunes Redox State. International journal of cell biology. 2012; 2012:161837. doi: 10.1155/2012/161837 PMID: 22888353
10. Cattaneo MG, Cappellini E, Benfante R, Ragni M, Omodeo-Sale F, Nisoli E, et al. Chronic deficiency of nitric oxide affects hypoxia inducible factor-1alpha (HIF-1alpha) stability and migration in human endothelial cells. PLOS One. 2011; 6(12):e29680. doi: 10.1371/journal.pone.0029680 PMID: 22216344
11. Graeber TG, Osmanian C, Jacks T, Housman DE, Koch CJ, Lowe SW, et al. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature. 1996; 379(6560):88-91. PMID: 8538748
12. Bindra RS, Glazer PM. Genetic instability and the tumor microenvironment: towards the concept of mi-croenvironment-induced mutagenesis. Mutat Res. 2005; 569(1-2):75-85. PMID: 15603754
13. Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med. 2012; 366(10):883-892. doi: 10.1056/NEJMoa1113205 PMID: 22397650
14. Yachida S, Jones S, Bozic I, Antal T, Leary R, Fu B, et al. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature. 2010; 467(7319):1114-1117. doi: 10.1038/nature09515 PMID: 20981102
15. Sottoriva A, Spiteri I, Piccirillo SG, Touloumis A, Collins VP, Marioni JC, et al. Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics. Proc Natl Acad Sci U S A. 2013; 110 (10):4009-4014. doi: 10.1073/pnas.1219747110 PMID: 23412337
16. Bayer C, Vaupel P. Acute versus chronic hypoxia in tumors: Controversial data concerning time frames and biological consequences. Strahlenther Onkol. 2012; 188(7):616-627. doi: 10.1007/s00066-012-0085-4 PMID: 22454045
17. Wykoff CC, Beasley NJ, Watson PH, Turner KJ, Pastorek J, Sibtain A, et al. Hypoxia-inducible expression of tumor-associated carbonic anhydrases. Cancer Res. 2000; 60(24):7075-7083. PMID: 11156414
18. Airley R, Loncaster J, Davidson S, Bromley M, Roberts S, Patterson A, et al. Glucose transporter glut-1 expression correlates with tumor hypoxia and predicts metastasis-free survival in advanced carcinoma of the cervix. Clin Cancer Res. 2001; 7(4):928-934. PMID: 11309343
19. Helmlinger G, Yuan F, Dellian M, Jain RK. Interstitial pH and pO2 gradients in solid tumors in vivo: high-resolution measurements reveal a lack of correlation. Nature medicine. 1997; 3(2):177-182. PMID: 9018236
20. Dewhirst MW, Kimura H, Rehmus SW, Braun RD, Papahadjopoulos D, Hong K, et al. Microvascular studies on the origins of perfusion-limited hypoxia. Br J Cancer Suppl. 1996; 27(51):S247-251. PMID: 8763890
21. Braun RD, Lanzen JL, Dewhirst MW. Fourier analysis of fluctuations of oxygen tension and blood flow in R3230Ac tumors and muscle in rats. Am J Physiol. 1999;277(2 Pt 2:) :H551-568.
22. Baudelet C, Cron GO, Ansiaux R, Crokart N, DeWever J, Feron O, et al. The role of vessel maturation and vessel functionality in spontaneous fluctuations of T2∗-weighted GRE signal within tumors. NMR in biomedicine. 2006; 19(1):69-76. PMID: 16411170
23. Gilead A, Neeman M. Dynamic remodeling of the vascular bed precedes tumor growth: MLS ovarian carcinoma spheroids implanted in nude mice. Neoplasia. 1999; 1(3):226-230. PMID: 10935477
24. Bindra RS, Crosby ME, Glazer PM. Regulation of DNA repair in hypoxic cancer cells. Cancer Metastasis Rev. 2007; 26(2):249-260. PMID: 17415527
25. Meng AX, Jalali F, Cuddihy A, Chan N, Bindra RS, Glazer PM, et al. Hypoxia down-regulates DNA double strand break repair gene expression in prostate cancer cells. Radiother Oncol. 2005; 76(2):168-176. PMID: 16026872
26. Young SD, Marshall RS, Hill RP. Hypoxia induces DNA overreplication and enhances metastatic potential of murine tumor cells. Proc Natl Acad Sci U S A. 1988; 85(24):9533-9537. PMID: 3200838
27. Greijer AE, van der Wall E. The role of hypoxia inducible factor 1 (HIF-1) in hypoxia induced apoptosis. J Clin Pathol. 2004; 57(10):1009-1014. PMID: 15452150
28. Santore MT, McClintock DS, Lee VY, Budinger GR, Chandel NS. Anoxia-induced apoptosis occurs through a mitochondria-dependent pathway in lung epithelial cells. Am J Physiol Lung Cell Mol Physiol. 2002; 282(4):L727-734. PMID: 11880298
29. Gillies RJ, Verduzco D, Gatenby RA. Evolutionary dynamics of carcinogenesis and why targeted therapy does not work. Nature reviews. 2012; 12(7):487-493. doi: 10.1038/nrc3298 PMID: 22695393
30. Pires IM, Bencokova Z, Milani M, Folkes LK, Li JL, Stratford MR, et al. Effects of acute versus chronic hypoxia on DNA damage responses and genomic instability. Cancer Res. 2010; 70(3):925-935. doi: 10.1158/0008-5472.CAN-09-2715 PMID: 20103649
31. Piret JP, Cosse JP, Ninane N, Raes M, Michiels C. Hypoxia protects HepG2 cells against etoposide-induced apoptosis via a HIF-1-independent pathway. Exp Cell Res. 2006; 312(15):2908-2920. PMID: 16844113
32. Cosse JP, Sermeus A, Vannuvel K, Ninane N, Raes M, Michiels C. Differential effects of hypoxia on etoposide-induced apoptosis according to the cancer cell lines. Mol Cancer. 2007; 6:61. PMID: 17894897
33. Rice GC, Hoy C, Schimke RT. Transient hypoxia enhances the frequency of dihydrofolate reductase gene amplification in Chinese hamster ovary cells. Proc Natl Acad Sci U S A. 1986; 83(16):5978-5982. PMID: 3461470
34. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000; 100(1):57-70. PMID: 10647931
35. Nollet F, Berx G, van Roy F. The role of the E-cadherin/catenin adhesion complex in the development and progression of cancer. Mol Cell Biol Res Commun. 1999; 2(2):77-85. PMID: 10542129
36. Kadota M, Yang HH, Gomez B, Sato M, Clifford RJ, Meerzaman D, et al. Delineating genetic alterations for tumor progression in the MCF10A series of breast cancer cell lines. PLOS One. 2010; 5(2):e9201. doi: 10.1371/journal.pone.0009201 PMID: 20169162
37. Wojtkowiak JW, Rothberg JM, Kumar V, Schramm KJ, Haller E, Proemsey JB, et al. Chronic autophagy is a cellular adaptation to tumor acidic pH microenvironments. Cancer Res. 2012; 72(16):3938-3947. doi: 10.1158/0008-5472.CAN-11-3881 PMID: 22719070
38. Brazdova M, Navratilova L, Tichy V, Nemcova K, Lexa M, Hrstka R, et al. Preferential binding of hot spot mutant p53 proteins to supercoiled DNA in vitro and in cells. PLOS One. 2013; 8(3):e59567. doi: 10.1371/journal.pone.0059567 PMID: 23555710
39. Vikhanskaya F, Siddique MM, Kei Lee M, Broggini M, Sabapathy K. Evaluation of the combined effect of p53 codon 72 polymorphism and hotspot mutations in response to anticancer drugs. Clin Cancer Res. 2005; 11(12):4348-4356. PMID: 15958617
40. Benjamini Y, Hochberg Y. Controlling the false discovery rate: A practical and powerful approach to multiple testing. J R Stat Soc Series B Stat Methadol. 1995; 57(1):289-300.
41. Storey JD, Tibshirani R. Statistical significance for genomewide studies. Proc Natl Acad Sci U S A. 2003; 100(16):9440-9445. PMID: 12883005
42. Tsai YP, Wu KJ. Hypoxia-regulated target genes implicated in tumor metastasis. J Biomed Sci. 2012; 19:102. doi: 10.1186/1423-0127-19-102 PMID: 23241400
43. Yang MH, Wu MZ, Chiou SH, Chen PM, Chang SY, Liu CJ, et al. Direct regulation of TWIST by HIF-1alpha promotes metastasis. Nat Cell Biol. 2008; 10(3):295-305. doi: 10.1038/ncb1691 PMID: 18297062
44. Ginzinger DG, Godfrey TE, Nigro J, Moore DH 2nd, Suzuki S, Pallavicini MG, et al. Measurement of DNA copy number at microsatellite loci using quantitative PCR analysis. Cancer Res. 2000; 60(19): 5405-5409. PMID: 11034080
45. Gatenby RA, Gillies RJ. Why do cancers have high aerobic glycolysis? Nature reviews. 2004; 4(11): 891-899. PMID: 15516961
46. Yun J, Rago C, Cheong I, Pagliarini R, Angenendt P, Rajagopalan H, et al. Glucose deprivation contributes to the development of KRAS pathway mutations in tumor cells. Science. 2009; 325(5947): 1555-1559. doi: 10.1126/science.1174229 PMID: 19661383
47. Yachida S, Iacobuzio-Donahue CA. Evolution and dynamics of pancreatic cancer progression. Oncogene. 2013; 18(10):29.
48. Lengauer C, Kinzler KW, Vogelstein B. Genetic instabilities in human cancers. Nature. 1998; 396 (6712):643-649. PMID: 9872311
49. Gillies RJ, Robey I, Gatenby RA. Causes and consequences of increased glucose metabolism of cancers. J Nucl Med. 2008; 49 Suppl 2(2):24S-42S. doi: 10.2967/jnumed.107.047258 PMID: 18523064
50. Dewhirst MW. Intermittent hypoxia furthers the rationale for hypoxia-inducible factor-1 targeting. Cancer Res. 2007; 67(3):854-855. PMID: 17283112
51. Giatromanolaki A, Koukourakis MI, Sivridis E, Pastorek J, Wykoff CC, Gatter KC, et al. Expression of hypoxia-inducible carbonic anhydrase-9 relates to angiogenic pathways and independently to poor outcome in non-small cell lung cancer. Cancer Res. 2001; 61(21):7992-7998. PMID: 11691824
52. Chia SK, Wykoff CC, Watson PH, Han C, Leek RD, Pastorek J, et al. Prognostic significance of a novel hypoxia-regulated marker, carbonic anhydrase IX, in invasive breast carcinoma. J Clin Oncol. 2001; 19(16):3660-3668. PMID: 11504747
53. Generali D, Berruti A, Brizzi MP, Campo L, Bonardi S, Wigfield S, et al. Hypoxia-inducible factor-1alpha expression predicts a poor response to primary chemoendocrine therapy and disease-free survival in primary human breast cancer. Clin Cancer Res. 2006; 12(15):4562-4568. PMID: 16899602
54. Jubb AM, Buffa FM, Harris AL. Assessment of tumour hypoxia for prediction of response to therapy and cancer prognosis. J Cell Mol Med. 2010; 14(1-2):18-29.
55. Gillies RJ, Gatenby RA. Hypoxia and adaptive landscapes in the evolution of carcinogenesis. Cancer Metastasis Rev. 2007; 26(2):311-317. PMID: 17404691
56. Gatenby RA, Smallbone K, Maini PK, Rose F, Averill J, Nagle RB, et al. Cellular adaptations to hypoxia and acidosis during somatic evolution of breast cancer. Br J Cancer. 2007; 97(5):646-653. PMID: 17687336
57. Ibrahim-Hashim A, Cornnell HH, Abrahams D, Lloyd M, Bui M, Gillies RJ, et al. Systemic buffers inhibit carcinogenesis in TRAMP mice. J Urol. 2012; 188(2):624-631. doi: 10.1016/j.juro.2012.03.113 PMID: 22704445
58. Bailey KM, Wojtkowiak JW, Hashim AI, Gillies RJ. Targeting the metabolic microenvironment of tumors. Adv Pharmacol. 2012; 65:63-107. doi: 10.1016/B978-0-12-397927-8.00004-X PMID: 22959024
59. Gatenby RA, Gillies RJ, Brown JS. Evolutionary dynamics of cancer prevention. Nature reviews. 2010; 10(8):526-527. PMID: 21137109